Cargando…
Early Conversion to Aflibercept for Persistent Diabetic Macular Edema Results in Better Visual Outcomes and Lower Treatment Costs
PURPOSE: To evaluate the functional and anatomic outcomes, as well as cost-effectiveness, of the timing of conversion to intravitreal aflibercept (IVA) in patients with treatment-resistant diabetic macular edema (DME). METHODS: Thirty consecutive eyes (25 patients) were identified that were treated...
Autores principales: | Ramsey, David J, Poulin, Samuel J, LaMonica, Lauren C, Blaha, Gregory R, Barouch, Fina C, Chang, Jeffrey, Marx, Jeffrey L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802895/ https://www.ncbi.nlm.nih.gov/pubmed/33447009 http://dx.doi.org/10.2147/OPTH.S286665 |
Ejemplares similares
-
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015) -
The role of aflibercept in the management of diabetic macular edema
por: Chang, Andrew A, et al.
Publicado: (2015) -
The clinical utility of aflibercept for diabetic macular edema
por: Stewart, Michael W
Publicado: (2015) -
One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
por: Abouhussein, Mahmoud Alaa, et al.
Publicado: (2021) -
Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
por: Petrovic, Nenad, et al.
Publicado: (2023)